Search form

Home
LoginSubscribe
  • Home
  • Country Intelligence
  • Industry Directory
  • Offsets / IC
  • Tenders
    • Haiti(0/week)
    • Guyana(0/week)
    • Honduras(0/week)
    • Jamaica(0/week)
    • Netherlands Antilles(0/week)
    • View all (0/week)
  • News
    • United States(1133/week)
    • Manufacturing(603/week)
    • Technology(1091/week)
    • Energy(452/week)
    • Other Manufacturing(400/week)
  • Events
  • About us
    • Who we are
    • Our People
    • Partners
    • Contact us
  • LinkedIn
  • Login
  • Twitter
  • Register
  • Home
  • News

CStone Pharmaceuticals

Mar 27, 2025
CStone Pharmaceuticals Announces 2024 Annual Results and Recent Business Progress
Mar 25, 2025
CStone to Showcase Five Latest Research Achievements at AACR 2025
Mar 23, 2025
CStone Submits Application to the European Medicines Agency for New Indication of Sugemalimab in Stage III Non-Small Cell Lung Cancer
Mar 05, 2025
CStone Submits Clinical Trial Application in Australia for CS5001 (ROR1 ADC) in Combination with First-Line Standard-of-Care for DLBCL
Mar 03, 2025
CStone Announces First Patient Dosed in Global Multicenter Phase I Clinical Trial of CS2009, a PD-1/VEGF/CTLA-4 Trispecific Antibody
Feb 09, 2025
CStone Announces Inclusion of Cejemly® (sugemalimab) as a First-Line Combination Therapy for NSCLC in ESMO Guideline
Jan 26, 2025
CStone Partners with SteinCares to Market Sugemalimab in Latin America
Dec 22, 2024
CStone Announces Submission of Clinical Trial Application in Australia for CS2009, an Innovative PD-1/VEGF/CTLA-4 Trispecific Antibody
Dec 08, 2024
Encouraging Efficacy and Safety: CStone Presents Latest Clinical Data on CS5001 for Advanced Lymphoma at the 66th ASH Annual Meeting
Oct 28, 2020
CStone and LegoChem Biosciences Enter Global Licensing Agreement for New Antibody Drug Conjugate
Oct 26, 2020
CStone and EQRx Enter Global Strategic Partnership for Two Immune Checkpoint Inhibitors: sugemalimab (anti-PD-L1) and CS1003 (anti-PD-1)
Oct 11, 2020
CStone Announces Completion of $200 million Share Sale to Pfizer
Aug 30, 2020
CStone Receives US FDA IND Clearance for CS1001-201 Study to Evaluate Anti-PD-L1 Monoclonal Antibody Sugemalimab Monotherapy in R/R ENKTL
Apr 22, 2020
CStone announces acceptance of its first New Drug Application in mainland China by the National Medical Products Administration, for the first-in-class precision therapy avapritinib in two gastrointestinal stromal tumor indications
Jan 24, 2020
CStone announces first patient dosed in the global proof-of-concept study of CS1001 in combination with Bayer's regorafenib
Jan 23, 2020
CStone successfully hosted the first U.S. R&D Day in New York
Jan 08, 2020
CStone announces first patient dosed in the Phase III trial of CS1001 in combination with chemotherapy in first-line esophageal squamous cell carcinoma
Jan 06, 2020
CStone Pharmaceuticals and Blueprint Medicines Initiate Phase 1b/2 Clinical Trial of Fisogatinib in Combination with CS1001 for Patients with Hepatocellular Carcinoma
Dec 12, 2019
CStone completes registration filing for the Phase I trial of its tumor immune microenvironment modulator CS3005 to enable study initiation in Australia
Dec 10, 2019
CStone announces enrollment target reached in the global Phase III VOYAGER trial of avapritinib in Chinese patients with third-line GIST
  •  
  • Page 1
  • ››

Latest News

Jul 30, 2025

dynaCERT Appoints John Amodeo as Director, Expanding Global Sales Strategy

Jul 30, 2025

Faraday Future to Present at the J.P. Morgan Auto Investor Conference in New York on August 12, 2025

Jul 30, 2025

QinetiQ US Secures $26 Million in Naval Defense Contracts with General Dynamics Electric Boat for Next-...

Jul 30, 2025

Northrop Grumman Tests Sentinel Missile Stage-Two Rocket Motor

Jul 30, 2025

Lockheed Martin Delivers 250th MK 48 Guidance and Control Section

Jul 30, 2025

RTX's Raytheon introduces advanced targeting system for U.S. Navy helicopters

Jul 30, 2025

Compass Minerals Announces Conference Call to Discuss Third-Quarter Fiscal 2025 Results

Jul 30, 2025

Delek Logistics Partners, LP Increases Quarterly Cash Distribution to $1.115 per Common Limited Partner Unit

View all News

Agenda

30
September
PortugalTroia, Portugal
Seabed Security, 30 September - 01 October 2025, Troia, Portugal
Seabed Security | 30 September - 01 October 2025 | Troia, Portugal Defence iQ Announces Inaugural Seabed Security...
23
September
United KingdomLondon, UK
Countering Explosive Threat & Demining conference, September 23 - 24, 2025, London, UK
Countering Explosive Threat & Demining conference | September 23 - 24, 2025 | London, UK The Countering Explosive...
View All Events

SUBSCRIBE

to Epicos.com
Please register in order to have access to personalized daily information on world-wide A&D industry developments and business opportunities.
Subscribe

REGISTER

for Epicos.com Newsletter
Sign up for our free newsletters and receive twice a week news and intelligence regarding the Aerospace & Defence Industry, meticulously selected by our editorial team.
Sign Up
Home
  • SIGN UP FOR NEWSLETTER
  • NEWSLETTER ARCHIVE
  • ADVERTISE WITH US
  • CONTACT US
  • PRIVACY POLICY
  • INFORMATION SECURITY POLICY
© 2025 EPICOS
Made by Wedia